RxDoctor Payments Data

William Lagaly, DO

Undersea and Hyperbaric Medicine · Athens, GANPI 1356371272

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Smith+Nephew at 32.9% of the total. Reporting peaked in 2019 at $734 and has fallen 70.9% since, to $213 in 2025.

$1,808in general payments, 2019–2025

Across 123 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$594
  • AbbVie$257
  • Organogenesis Inc.$117
  • Convatec Inc.$114
  • Solventum Corporation$82
  • Misonix Inc$80
  • plus $563 from 19 others

What the payments were for

  • Food & beverage$1,808100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few undersea and hyperbaric medicine providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$79,829
Medicare patients
239
Services billed
1,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.46$56,105
Doxycycline Hyclate50$541
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip23$353
Lidocaine-PrilocaineLidocaine/Prilocaine15$207
Levofloxacin24$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$594$56,10546 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few undersea and hyperbaric medicine providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other undersea and hyperbaric medicine in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →